Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. Dabigatran etexilate was approved by the FDA in 2010. Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran].
Dabigatran Etexilate
| API Name | Alogliptin benzoate |
|---|---|
| CAS No | 211915-06-9 |
| Molecular Formula | C34H41N7O5 |
| Molecular Weight | 627.7 g/mol |
| Synonyms | ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate |
Zoho Contact Form - Pharma Intermediates
"*" indicates required fields
Frequently Asked Questions
Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. Dabigatran etexilate was approved by the FDA in 2010. Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran].
The CAS number of Dabigatran Etexilate is 211915-06-9.
The molecular formula of Dabigatran Etexilate is C34H41N7O5.
The listed molecular weight of Dabigatran Etexilate is 627.7 g/mol.
Dabigatran Etexilate is listed as being used in connection with the following API: Alogliptin benzoate.
The listed synonym or IUPAC name for Dabigatran Etexilate is ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate.